Values as of: 2025-02-21
COMMON STOCK | Medical Devices |
Last Closing
USD 18.6Change
0.00 (0.00)%Market Cap
USD 11.60BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, it offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; and lab assay services. Further, the company is involved in the development and sale of software for diagnostic information systems; provision of facility management, office, welfare, and genetic analysis services; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. Additionally, it researches, develops, manufactures, and sells regenerative medicine products; develops, manufactures, and sells biodevices; develops, maintains, and sells computer software; and offers blood DNA testing service. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
Company Website : https://www.sysmex.co.jp
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| SEMHF | Siemens Healthineers AG |
N/A |
USD 67.08B |
| SMMNY | Siemens Healthineers AG ADR |
+0.14 (+0.49%) |
USD 66.51B |
| RYLPF | Koninklijke Philips N.V |
+1.04 (+4.19%) |
USD 25.99B |
| SONVF | Sonova Holding AG |
-4.98 (-1.48%) |
USD 20.26B |
| OCPNF | Olympus Corporation |
N/A |
USD 17.48B |
| AULSF | AULSF |
N/A |
USD 17.01B |
| SNNUF | Smith & Nephew plc |
N/A |
USD 11.22B |
| WILLF | Demant A/S |
N/A |
USD 9.04B |
| GNGBF | Getinge AB |
N/A |
USD 5.34B |
| AMBBY | Ambu A/S |
N/A |
USD 4.96B |
N/A
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -3.73% | 33% | F | 33% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -3.73% | 33% | F | 33% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -68.45% | 23% | F | 12% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -68.45% | 23% | F | 12% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -74.45% | 38% | F | 28% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -74.45% | 38% | F | 27% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -9.21% | 27% | F | 23% | F | ||
| Dividend Return | 24.64% | 78% | C+ | 65% | D | ||
| Total Return | 33.85% | 96% | N/A | 95% | A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 73.90% | 34% | F | 41% | F | ||
| Risk Adjusted Return | 33.34% | 84% | B | 70% | C- | ||
| Market Capitalization | 11.60B | 94% | A | 92% | A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
